Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (SBIR [R43/R44])

The summary for the Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (SBIR [R43/R44]) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (SBIR [R43/R44]): Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to define the factors and mechanisms controlling the differentiation of embryonic or adult stem or progenitor cells, either in vitro or in vivo. It is designed to stimulate new scientific advances in stem cell differentiation including technology research that may not be hypothesis driven. The long-range goal of this program is the development of methods to direct the differentiation or development of stem cells along specific cell lineages to yield replacement cells for clinical use, whether the replacement cells are formed in vitro for delivery or formed in vivo in the tissue or organ environment. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with FOAs of identical scientific scope, PA-09-250, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms, and PA-09-248 that encourages applications under the Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.